Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Non-cash Items: 2013-2018

Historic Non-cash Items for Amicus Therapeutics (FOLD) over the last 5 years, with Mar 2018 value amounting to $40.6 million.

  • Amicus Therapeutics' Non-cash Items rose 9.14% to $40.6 million in Q1 2018 from the same period last year, while for Mar 2018 it was $40.6 million, marking a year-over-year increase of 9.14%. This contributed to the annual value of $105.8 million for FY2017, which is 213.95% up from last year.
  • As of Q1 2018, Amicus Therapeutics' Non-cash Items stood at $40.6 million, which was down 61.63% from $105.8 million recorded in Q4 2017.
  • In the past 5 years, Amicus Therapeutics' Non-cash Items registered a high of $105.8 million during Q4 2017, and its lowest value of $5.3 million during Q3 2015.
  • Moreover, its 3-year median value for Non-cash Items was $34.7 million (2017), whereas its average is $31.5 million.
  • Within the past 5 years, the most significant YoY rise in Amicus Therapeutics' Non-cash Items was 1,302.20% (2017), while the steepest drop was 75.76% (2017).
  • Quarterly analysis of 5 years shows Amicus Therapeutics' Non-cash Items stood at $5.4 million in 2014, then crashed by 69.87% to $5.3 million in 2015, then soared by 575.12% to $7.5 million in 2016, then spiked by 1,302.20% to $105.8 million in 2017, then rose by 9.14% to $40.6 million in 2018.
  • Its last three reported values are $40.6 million in Q1 2018, $105.8 million for Q4 2017, and $8.7 million during Q3 2017.